{"id":"W2987946496","doi":"10.1093/neuonc/noz175.073","title":"ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Trametinib; Medicine; Dabrafenib; Internal medicine; Oncology; Glioma; Progression-free survival; Discontinuation; Interim analysis; Clinical endpoint; MEK inhibitor; Clinical trial; Chemotherapy; Cancer; Cancer research; MAPK/ERK pathway; Vemurafenib; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001484493,0.0003896104,0.001094317,0.0003553863,0.0001895811,0.0005911298,0.000360155,0.0003470643,0.002359984],"category_scores_gemma":[0.0008326264,0.0001824245,0.001041699,0.0003454982,0.0002219674,0.0004638152,0.000177375,0.0008708805,0.0006939347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006670497,"about_ca_system_score_gemma":0.000882096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009693635,"about_ca_topic_score_gemma":0.003938369,"domain_scores_codex":[0.9994022,0.0002811563,0.00004842822,0.00009390608,0.0001067673,0.00006760364],"domain_scores_gemma":[0.9995012,0.00007669523,0.0001667672,0.00004546695,0.00006043433,0.0001493234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3715264,0.008804747,0.07040617,0.001535376,0.003639204,0.0006696995,0.0002577862,0.006101985,0.05375874,0.0006014216,0.01867373,0.4640248],"study_design_scores_gemma":[0.2771899,0.2818467,0.3644373,0.0002832541,0.006607444,0.003909215,0.0002056352,0.01223484,0.01953482,0.001076035,0.0325206,0.0001542651],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845695,0.005219059,0.0005477882,0.0003812174,0.00008152345,0.0005760737,0.003445031,0.0001829243,0.004996764],"genre_scores_gemma":[0.9921343,0.0009978118,0.0007887603,0.0003479662,0.00006246043,0.0002655291,0.004387925,0.000017435,0.0009978659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002359984,"threshold_uncertainty_score":0.007894933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01139772099240635,"score_gpt":0.2691038434296475,"score_spread":0.2577061224372412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}